Although Daniel George, MD, of the Duke Cancer Institute, sees value in cancer vaccines and expects they will start showing more benefit to patients, he acknowledges that a barrier to widespread use of cancer vaccines is that they don't show an immediate response.
Although Daniel George, MD, of the Duke Cancer Institute, sees value in cancer vaccines and expects they will start showing more benefit to patients, he acknowledges that a barrier to widespread use of cancer vaccines is that they don't show an immediate response.
Transcript
What is your outlook on cancer vaccines, and what do you think has been a barrier to preventing widespread use?
So immunotherapy is exciting because of the checkpoint inhibitors, but let's not forget that there is absolutely more to the immune system than PD-1, PD-L1 target. And I personally believe that cancer vaccines will show more and more benefit in the future in patients. In prostate cancer we have the sipuleucel-T strategy, which is a cancer vaccine of sorts, where we're activating autologous antigen-presenting cells to stimulate the immune system. And I do see a role for both stimulating the immune system as well as releasing checkpoints in combination or in sequence in the future.
I think one of the problems has been that with vaccines they take time to work. And because of that we don't typically see an immediate response. And in oncology, we're kind of trained to a culture of looking for a response to agents to guide our practice, whether it be chemotherapy, hormonal therapy, or even now checkpoint inhibitors. So I do see that as somewhat of a stumbling block in being able to show the value.
Ultimately, vaccines should show an improvement in overall survival, of disease-free survival in the adjuvant setting, or what have you. So I do look forward to them in the future, but I think they're going to take longer, slower trials to show their benefit.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More